SAB Biotherapeutics
SABS
76 hedge funds and large institutions have $265M invested in SAB Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 5 closing their positions.
580% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 5
243% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 7
116% more call options, than puts
Call options by funds: $611K | Put options by funds: $283K
95% more capital invested
Capital invested by funds: $136M → $265M (+$129M)
59.46% more ownership
Funds ownership: 76.34% → 135.8% (+59%)
58% more funds holding
Funds holding: 48 → 76 (+28)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
+$31.8M |
| 2 |
PA
Perceptive Advisors
New York
|
+$22.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$13.6M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$13.1M |
| 5 |
Millennium Management
New York
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$5.12M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$100K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$98.5K |
| 4 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$83.7K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$70.4K |
SABS Hedge Fund Activity: Q1 2026 in Review
76 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q1 2026, worth a combined $265M — up 95% from $136M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new SABS positions and 5 closed out — a net gain of 29 holders — while 24 added to existing stakes and 7 trimmed.
The largest buyer was Caligan Partners, opening a new position worth an estimated $31.8M. The largest seller was Blackstone Inc, cutting an estimated $5.12M.
- 76 institutional investors held SAB Biotherapeutics (SABS) as of Q1 2026, up from 48 in Q4 2025.
- Funds reported $265M of SAB Biotherapeutics stock for Q1 2026, up 95% quarter-over-quarter.
- 34 funds opened new SAB Biotherapeutics positions in Q1 2026 and 5 closed out, a net change of +29 holders.
- The largest SAB Biotherapeutics buyer in Q1 2026 was Caligan Partners, an estimated $31.8M added.
- The largest SAB Biotherapeutics seller in Q1 2026 was Blackstone Inc, an estimated $5.12M sold.
Based on aggregated 13F filings for Q1 2026.